Katie M. Campbell

Katie M. Campbell

Auto-generated profile, based on publicly available information

Katie M. Campbell

Department of Medicine, Division of Hematology-Oncology, University of California – Los Angeles (UCLA), Los Angeles, CA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MGMalachi Griffith
Malachi Griffith
NSNicholas C Spies
Nicholas C Spies
KKKilannin Krysiak
Kilannin Krysiak
JMJoshua F McMichael
Joshua F McMichael
ACAdam C Coffman
Adam C Coffman
OGObi L Griffith
Obi L Griffith
CIViC is an expert-crowdsourced knowledgebase for Clinical Interpretation of Variants in Cancer describing the therapeutic, prognostic, diagnostic and predisposing relevance of inherited and somatic variants of all types. CIViC is committed to open-source code, open-access content, public application programming interfaces (APIs) and provenance of supporting evidence to allow for the transparent creation of current and accurate variant interpretations for use in cancer precision medicine.

1 October 2020 in Cell
Verified
Journal Article
Closed access
DWDaniel K Wells
Daniel K Wells
MBMarit M van Buuren
Marit M van Buuren
KDKristen K Dang
Kristen K Dang
VHVanessa M Hubbard-Lucey
Vanessa M Hubbard-Lucey
KSKathleen C F Sheehan
Kathleen C F Sheehan
NDNadine A Defranoux
Nadine A Defranoux

3 November 2015 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
AWAlex H. Wagner
Alex H. Wagner
ACAdam C. Coffman
Adam C. Coffman
BABenjamin J. Ainscough
Benjamin J. Ainscough
NSNicholas C. Spies
Nicholas C. Spies
ZSZachary L. Skidmore
Zachary L. Skidmore
OGObi L. Griffith
Obi L. Griffith
The Drug–Gene Interaction Database (DGIdb, www.dgidb.org) is a web resource that consolidates disparate data sources describing drug–gene interactions and gene druggability. It provides an intuitive graphical user interface and a documented application programming interface (API) for querying these data. DGIdb was assembled through an extensive manual curation effort, reflecting the combined information of twenty-seven sources. For DGIdb 2.0, substantial updates have been made to increase content and improve its usefulness as a resource for mining clinically actionable drug targets. Specifically, nine new sources of drug–gene interactions have been added, including seven resources specifically focused on interactions linked to clinical trials. These additions have more than doubled the overall count of drug–gene interactions. The total number of druggable gene claims has also increased by 30%. Importantly, a majority of the unrestricted, publicly-accessible sources used in DGIdb are now automatically updated on a weekly basis, providing the most current information for these sources. Finally, a new web view and API have been developed to allow searching for interactions by drug identifiers to complement existing gene-based search functionality. With these updates, DGIdb represents a comprehensive and user friendly tool for mining the druggable genome for precision medicine hypothesis generation.

14 July 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RURavindra Uppaluri
Ravindra Uppaluri
KCKatie M. Campbell
Katie M. Campbell
AEAnn Marie Egloff
Ann Marie Egloff
PZPaul Zolkind
Paul Zolkind
ZSZachary L. Skidmore
Zachary L. Skidmore
DADouglas R. Adkins
Douglas R. Adkins
Purpose: Pembrolizumab improved survival in patients with recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). The aims of this study were to determine if pembrolizumab would be safe, result in pathologic tumor response (pTR), and lower the relapse rate in patients with resectable human papillomavirus (HPV)–unrelated HNSCC. Patients and Methods: Neoadjuvant pembrolizumab (200 mg) was administered and followed 2 to 3 weeks later by surgical tumor ablation. Postoperative (chemo)radiation was planned. Patients with high-risk pathology (positive margins and/or extranodal extension) received adjuvant pembrolizumab. pTR was quantified as the proportion of the resection bed with tumor necrosis, keratinous debris, and giant cells/histiocytes: pTR-0 (<10%), pTR-1 (10%–49%), and pTR-2 (≥50%). Coprimary endpoints were pTR-2 among all patients and 1-year relapse rate in patients with high-risk pathology (historical: 35%). Correlations of baseline PD-L1 and T-cell infiltration with pTR were assessed. Tumor clonal dynamics were evaluated (ClinicalTrials.gov NCT02296684). Results: Thirty-six patients enrolled. After neoadjuvant pembrolizumab, serious (grades 3–4) adverse events and unexpected surgical delays/complications did not occur. pTR-2 occurred in eight patients (22%), and pTR-1 in eight other patients (22%). One-year relapse rate among 18 patients with high-risk pathology was 16.7% (95% confidence interval, 3.6%–41.4%). pTR ≥10% correlated with baseline tumor PD-L1, immune infiltrate, and IFNγ activity. Matched samples showed upregulation of inhibitory checkpoints in patients with pTR-0 and confirmed clonal loss in some patients. Conclusions: Among patients with locally advanced, HPV-unrelated HNSCC, pembrolizumab was safe, and any pathologic response was observed in 44% of patients with 0% pathologic complete responses. The 1-year relapse rate in patients with high-risk pathology was lower than historical.

10 June 2016 in Bioinformatics
Verified
Journal Article
Open access
PDF file
ZSZachary L. Skidmore
Zachary L. Skidmore
AWAlex H. Wagner
Alex H. Wagner
RLRobert Lesurf
Robert Lesurf
KCKatie M. Campbell
Katie M. Campbell
JKJason Kunisaki
Jason Kunisaki
MGMalachi Griffith
Malachi Griffith
Summary: Visualizing and summarizing data from genomic studies continues to be a challenge. Here, we introduce the GenVisR package to addresses this challenge by providing highly customizable, publication-quality graphics focused on cohort level genome analyses. GenVisR provides a rapid and easy-to-use suite of genomic visualization tools, while maintaining a high degree of flexibility by leveraging the abilities of ggplot2 and Bioconductor. Availability and Implementation: GenVisR is an R package available via Bioconductor (https://bioconductor.org/packages/GenVisR) under GPLv3. Support is available via GitHub (https://github.com/griffithlab/GenVisR/issues) and the Bioconductor support website. Contacts:obigriffith@wustl.edu or mgriffit@wustl.edu Supplementary information: Supplementary data are available at Bioinformatics online.

10 November 2022 in Nature
Verified
Journal Article
Open access
PDF file
SFSusan P. Foy
Susan P. Foy
KJKyle Jacoby
Kyle Jacoby
DBDaniela A. Bota
Daniela A. Bota
THTheresa Hunter
Theresa Hunter
ZPZheng Pan
Zheng Pan
SMStefanie J. Mandl
Stefanie J. Mandl
T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells1–3. Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision genome-editing to simultaneously knockout the two endogenous TCR genes TRAC (which encodes TCRα) and TRBC (which encodes TCRβ). We also inserted into the TRAC locus two chains of a neoantigen-specific TCR (neoTCR) isolated from circulating T cells of patients. The neoTCRs were isolated using a personalized library of soluble predicted neoantigen–HLA capture reagents. Sixteen patients with different refractory solid cancers received up to three distinct neoTCR transgenic cell products. Each product expressed a patient-specific neoTCR and was administered in a cell-dose-escalation, first-in-human phase I clinical trial (NCT03970382). One patient had grade 1 cytokine release syndrome and one patient had grade 3 encephalitis. All participants had the expected side effects from the lymphodepleting chemotherapy. Five patients had stable disease and the other eleven had disease progression as the best response on the therapy. neoTCR transgenic T cells were detected in tumour biopsy samples after infusion at frequencies higher than the native TCRs before infusion. This study demonstrates the feasibility of isolating and cloning multiple TCRs that recognize mutational neoantigens. Moreover, simultaneous knockout of the endogenous TCR and knock-in of neoTCRs using single-step, non-viral precision genome-editing are achieved. The manufacture of neoTCR engineered T cells at clinical grade, the safety of infusing up to three gene-edited neoTCR T cell products and the ability of the transgenic T cells to traffic to the tumours of patients are also demonstrated.